Magazine

Issue 3-2018

Download Issue 3-2018 (pdf)

Letter from the Editor
Magnus Gisslén

Gemini Trials: the end of triplets?
José R Arribas

BHIVA -events
Rageshri Dhairyawan

Dolutegravir at conception
Graeme Moyle

Management of hepatitis E virus infection -a summary of the new EASL Clinical Practice Guidelines
Johannes Vermehren

Notes 2018
Leo Flamholc

Topical Conferences 2018-2019

Issue 2-2018

Download Issue 2-2018 (pdf)

Letter from the Editor
Magnus Gisslén

Hepatitis at the ILC
Per Lundblad

Satellite symposiums at the European ILC
Per Lundblad

BHIVA - events
Rageshri Dhairyawan

What’s new in hepatitis? A report from the International Liver Congress in Paris
Johannes Vermehren

Archived nucleos(t)ide resistance mutations in the era of high genetic barrier antiretrovirals: still matter?
José R Arribas

The new drugs in later lines of therapy
Graeme Moyle

Notes 2018
Leo Flamholc

Issue 1-2018

Download Issue 1-2018 (pdf)

Letter from the Editor
Magnus Gisslén

CROI in Boston 2018
Per Lundblad

European AIDS Conference 2017
Per Lundblad

BHIVA - resent events
Rageshri Dhairyawan

Satellite symposiums at the European AIDS Congress
Per Lundblad

The EASL 2017 Clinical Practice Guidelineson HBV infection
Johannes Vermehren

The thin harvest of studies of antiretroviral therapy in naïve
José R Arribas

The bad old days
Graeme Moyle

Notes 2018
Leo Flamholc

Issue 4-2017

Download Issue 4-2017 (pdf)

Letter from the Editor
Magnus Gisslén

HIV & Hepatitis Nordic Conference 2017
Per Lundblad

Satellite symposiums at the HIV & Hepatitis Nordic Conference
Per Lundblad

Hepatitis News from The Liver Meeting in Washington
Johannes Vermehren

BHIVA in HIV Nordic
Rageshri Dhairyawan

Antiretroviral therapy at EACS 2017: a bright(e) amber
José R Arribas

Challenging the holy trinity
Graeme Moyle

Notes 2017
Leo Flamholc

Issue 3-2017

Download Issue 3-2017 (pdf)

Letter from the Editor
Magnus Gisslén

GLE/PIB and SOF/VEL/VOX: the final nails in the coffin of HCV?
Johannes Vermehren

Back in business - a resistance report from Rome
Anders Sönnerborg

Antiretroviral therapy in experienced patients at IAS 2017
José A Arribas

What is the point of Bictegravir?
Graeme Moyle

Notes 2017
Leo Flamholc

Issue 2-2017

Download Issue 2-2017 (pdf)

Letter from the Editor
Magnus Gisslén

ILC in Amsterdam
Per Lundblad

Satellite Symposiums
Per Lundblad

No entry
José A Arribas

TAF for hepatitis B: improved safety profile or just a clever marketing?
Johannes Vermehren

Which is the best statin for HIV patients?
Graeme Moyle

Notes 2017
Leo Flamholc

Issue 1-2017

Download Issue 1-2017 (pdf)

Letter from the Editor
Magnus Gisslén

HIV Drug Therapy Glasgow 2016
Per Lundblad

Satellite Symposiums at HIV Glasgow 2016
Per Lundblad

Reduced Drug Regimens at CROI 2017
José A Arribas

HBV Reactivation in Patients Receiving DAAs for HCV
Johannes Vermehren

More sleepless nights
Graeme Moyle

Should we encourage women to breastfeed?
Chloe Orkin and Laura Byrne

Notes 2017
Leo Flamholc

Issue 4-2016

Download Issue 4-2016 (pdf)

Letter from the Editor
Magnus Gisslén

HIV & HCV Nordic Conference 2016
Per Lundblad

Satellite symposiums at the Nordic HIV & Hepatitis Conference
Per Lundblad

Dual therapies with boosted protease inhibitor and lamivudine
José A Arribas

Retreatment of patients in whom prior DAA therapy has failed
Johannes Vermehren

Breaking up is hard to do
Graeme Moyle

"Ecological ART"- news from HIV Glasgow 2016
Christine Katlama

Notes 2016
Leo Flamholc

Issue 3-2016

Download Issue 3-2016 (pdf)

Letter from the Editor
Magnus Gisslén

A Franco/Chinese SIV/HIV vaccine endeavor
Sven Britton

PADDLE and LATTE. The future of
antiretroviral therapy?
José A Arribas

Two new combination therapies
approved for the treatment of hepatitis C
Johannes Vermeheren

What’s new with Integrase Inhibitors?
Graeme Moyle

What’s New About Antiretroviral
Strategies?
Christine Katlama

Notes 2016
Leo Flamholc

 

Issue 2-2016

Download Issue 2-2016 (pdf)

Letter from the Editor
Magnus Gisslén

Hepatitis at the International Liver Congress 2016
Per Lundblad

Switching with confidence: the value of resistance testing in proviral DNA
José R Arribas

Future DAAs for the treatment of chronic hepatitis C infection
Johannes Vermehren

Where now for CCR5 antagonists?
Graeme Moyle

Meeting on cure in Stockholm
Per Lundblad

Notes 2016
Leo Flamholc

Pages